Caninized anti-NGF antibodies and methods thereof
The present disclosure describes novel caninized anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further describes use of the novel antibodies, antigen binding proteins and/or nucleotides of the invention for the treatment and/or prevention of NGF related disorders, particularly for the management of canine pain.
1. A method of treating a canine for pain comprising administering a therapeutically effective amount of a veterinary composition comprising a monoclonal antibody that specifically binds to canine Nerve Growth Factor comprising a variable heavy chain comprising SEQ ID NO. 27 and a variable light chain comprising SEQ ID NO. 26 further comprising a pharmaceutically acceptable carrier.
2. The method of claim 1 wherein the type of pain is selected from the group consisting of: chronic pain, inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, cancer pain, pain resulting from burns, pain associated with wounds, pain associated with trauma, neuropathic pain, pain associated with musculoskeletal disorders, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, seronegative (non-rheumatoid) arthropathies, non-articular rheumatism and periarticular disorders and peripheral neuropathy.
3. The method of claim 1 wherein the pain is osteoarthritis pain.